Eli Lilly Q3 Adjusted EPS $0.10 Beats $(0.15) Estimate, Sales $9.50B Beat $8.95B Estimate
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly reported Q3 earnings of $0.10 per share, beating the analyst consensus estimate of $(0.15) by 166.67%. This is a 94.95% decrease from the same period last year. The company also reported quarterly sales of $9.50 billion, beating the estimate of $8.95 billion by 6.13%, a 36.84% increase from last year.
November 02, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Q3 earnings and sales beat estimates, despite a significant decrease in earnings compared to the same period last year.
Eli Lilly's Q3 earnings and sales beat analyst estimates, which is generally a positive signal for the stock. However, the significant decrease in earnings compared to the same period last year may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100